• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Lawson, Stemcell Technologies partner on Parkinson’s

Lawson, Stemcell Technologies partner on Parkinson’s

August 27, 2015
CenterWatch Staff

Lawson Health Research Institute and Stemcell Technologies have signed a license agreement giving Stemcell global exclusive rights to commercialize novel tools for Parkinson’s disease research.

Lawson is the research institute of London Health Sciences Center and St. Joseph’s Health Care London, and works in partnership with Western University.

A team led by Dr. Matthew Hebb, a neurosurgeon-researcher at Lawson and Western University’s Department of Clinical Neurological Sciences, has been developing innovative strategies to study Parkinson’s.

Parkinson’s is the second-most common neurodegenerative disorder, after Alzheimer’s disease, affecting as many as 10 million people around the world. It is characterized by progressive neurological impairment that produces tremor, slowness of movement, impaired balance, muscle rigidity, cognitive decline and other medical disturbances. The symptoms are caused by the death of cells in the nervous system, including those that generate dopamine, a chemical neurotransmitter that sends signals between nerve cells. Although specific gene mutations have been identified in a minority of patients, there is no known cause in most individuals. There is currently no cure for Parkinson’s.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing